Skip to main content
SpringerLink
Log in

Psychiatrische Indikationen für Benzodiazepine

  • Conference paper
Nutzen und Gefahren der Therapie mit Benzodiazepinen

  • 20 Accesses

Zusammenfassung

Benzodiazepine werden von ihrem Wirkungsspektrum her zur Gruppe der Tranquilizer gerechnet. Geht man der klassischen Aufteilung der Psychopharmaka nach, so bilden die Tranquilizer neben den Neuroleptika und den Antidepressiva die dritte große Gruppe der Psychopharmaka.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ackenheil M (1985). Arzneimitteltherapie heute Band 36. Spektrum Psychopharmaka

    Google Scholar 

  2. AMDP (1979). Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie: Das AMDP-System: Manual zur Dokumentation psychiatrischer Befunde. 3. korr. u. erw. Aufl. Springer, Berlin, Heidelberg, New York

    Google Scholar 

  3. Beckmann H, Haas St (1980). High dose diazepam in schizophrenia. Psychopharmacology 71: 79–82

    Article  PubMed  CAS  Google Scholar 

  4. Crow TJ (1979). Biochemical effects of some new antidepressants: Putative mechanism of antidepressants effect. In: Dumont C (ed) Advances in pharmacology and therapeutics, Vol 5, Neuropsychopharmacology. Pergamon, Oxford

    Google Scholar 

  5. Feighner JP (1982). Benzodiazepines as antidepressants. In: Ban TA, Freyhan FA, Pöldinger W (eds) Modern Problems of Pharmacopsychiatry 18. Karger, Basel. 196–212

    Google Scholar 

  6. Guz I, Moraes R, Sartoretto IN (1972). The therapeutic effects of lorazepam in psychotic patients treated with haloperidol. Curr Ther Res 14: 767–774

    PubMed  CAS  Google Scholar 

  7. Hamilton M (1976a) 048 HAMA. Hamilton Anxiety Scale. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed NIMH, Rockville, Maryland, pp 193–198

    Google Scholar 

  8. Hamilton M (1976b) 049 HAMD. Hamilton Depression Scale. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed NIMH, Rockville, Maryland, pp 179–192

    Google Scholar 

  9. Hanlon TE, Ota KY, Agallianos DD, Bergmann SA, Bethon GD, Kobler F, Kurland AA (1969). Combined drug treatment of newly hospitalized acutely ill psychiatric patients. Dis Nerv Syst 30: 104–116

    PubMed  CAS  Google Scholar 

  10. Hanlon TE, Ota KY, Kurland AA (1970). Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide, and fluphenazineimipramine. Dis Nerv Syst 31: 171–177

    PubMed  CAS  Google Scholar 

  11. Hippius H (1972). The current status of treatment for depression. In: Kielholz P (ed) Depressive illness, diagnosis, assessment, treatment. Huber, Bern, pp 49–58

    Google Scholar 

  12. Janke W, Debus G (1977). Die Eigenschaftswörterliste (EWL) - Ein Verfahren zur Erfassung der Befindlichkeit. Hogrefe, Göttingen Toronto Zürich

    Google Scholar 

  13. Klein HE, Hippius H (1983). Angst-Diagnostik und Therapie in der täglichen Praxis. Adam Pharma Verlag GmbH, Essen

    Google Scholar 

  14. Kramer JC (1967). Treatment of chronic hallucinations with diazepam and phenothiazines. Dis Nerv Syst 28: 593–594

    PubMed  CAS  Google Scholar 

  15. Laakmann G, Blaschke D, Hippius H and Messerer D (1986). Alprazolam versus amitriptyline in the treatment of depressed out-patients: a randomized double-blind trial. In: Lader MH, Davies HC (eds) Drug treatment of neurotic disorders: focus on alprazolam. Churchill Livingstone, Edinburgh London Melbourne and New York

    Google Scholar 

  16. Langer G, Heimann H (1983). Psychopharmaka: Grundlagen und Therapie. Springer, Wien New York

    Google Scholar 

  17. Lingjaerde O, Engstrand E, Ellingson P, Stylo DA, Robak OH (1979). Antipsychotic effect of Diazepam when given in addition to neuroleptics in chronic psychotic patients. Curr Ther Res 26: 505–514

    Google Scholar 

  18. Michaux MH, Kurland AA, Agallianos DD (1966). Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Curr Ther Res 8 (supp): 117–152

    PubMed  Google Scholar 

  19. Nair NPV, Nestoros JN, Schwartz G (1981). High doses of diazepam improve neuroleptic-resistant schizophrenic patients. Abstract of the I II World Congress of Biological Psychiatry, Stockholm

    Google Scholar 

  20. NIMH (1976) 028 CGI. Clinical Global Impressions. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed National Institute of Mental Health, Rockville, Maryland, pp 217–222

    Google Scholar 

  21. Rickels K, Case WG, Downing RW (1982). Issues in long-term treatment with diazepam therapy. Psychopharmacol Bull 18: 38–41

    Google Scholar 

  22. Rickels K, Feighner JP, Smith WT (1985). A double-blind comparison of alprazolam, amitriptyline, doxepin and placebo in the treatment of major depression. Arch Gen Psychiatry 42: 134–141

    Article  PubMed  CAS  Google Scholar 

  23. Schatzberg AF, Cole JO (1978). Benzodiazepines in depressive disorders. Arch Gen Psychiatry 35: 1359–1365

    Article  PubMed  CAS  Google Scholar 

  24. Zung WW (1976) 073 SDS. Self-Rating Depression Scale. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Rev Ed NIMH, Rockville, Maryland, pp 333–336

    Google Scholar 

Download references

Authors
  1. G. Laakmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Blaschke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pharmakologie, Med. Einrichtungen der Universität Düsseldorf, Moorenstraße 5, 4000, Düsseldorf 1, Deutschland

    U. Borchard

  2. Rheinische Landesklinik, Psychiatrische Klinik der Universität Düsseldorf, Bergische Landstraße 2, 4000, Düsseldorf 12, Deutschland

    C. Haring

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Laakmann, G., Blaschke, D. (1987). Psychiatrische Indikationen für Benzodiazepine. In: Borchard, U., Haring, C. (eds) Nutzen und Gefahren der Therapie mit Benzodiazepinen. Steinkopff. https://doi.org/10.1007/978-3-642-85358-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85358-6_6

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-85359-3

  • Online ISBN: 978-3-642-85358-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation